ArticleClinical medicine (London, England)2018
Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist.
Article in Clinical medicine (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.Bone marrow transplantation · 2025Guideline
- Autologous immune system reset for kidney allograft acceptance: mechanisms, evidence, and a testable reconstitution-window model.Frontiers in medicine · 2026Review
- New autoimmune disorder development after immune reconstitution therapy for multiple sclerosis.Scientific reports · 2024Article
- Review
- Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults:JACC. CardioOncology · 2024Review
- Stem cell-based therapy for systemic lupus erythematous.Journal of translational autoimmunity · 2024Review
- HIV-1 proviral DNA in purified peripheral blood CD34Heliyon · 2024Article
- Immunological outcomes of autologous hematopoietic stem cell transplantation for multiple sclerosis: a systematic review.Annals of medicine and surgery (2012) · 2024Review
- Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.Lipids in health and disease · 2023Article
- Review
- Novel Therapies for Patients With Inflammatory Bowel Disease.Gastroenterology & hepatology · 2022Article
- Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives.Biology · 2022Review
- Effects of Posaconazole on Tacrolimus Population Pharmacokinetics and Initial Dose in Children With Crohn's Disease Undergoing Hematopoietic Stem Cell Transplantation.Frontiers in pharmacology · 2022Article
- Circulatory miR-155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation, a multivariate analysis.International journal of hematology · 2021Article
- Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis.Journal of blood medicine · 2021Review
- Autologous Hematopoietic Stem Cell Transplantation for Behçet's Disease: A Retrospective Survey of Patients Treated in Europe, on Behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.Frontiers in immunology · 2021Article
- Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies.Frontiers in medicine · 2021Review
- Selective cognitive dysfunction and physical disability improvement after autologous hematopoietic stem cell transplantation in highly active multiple sclerosis.Scientific reports · 2020Observational
- Medical, ethical, and legal aspects of hematopoietic stem cell transplantation for Crohn's disease in Brazil.World journal of stem cells · 2020Review
- Cladribine Tablets and Relapsing-Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know.Neurology and therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
Autologous haematopoietic stem cell transplantation (aHSCT) is commonly used for the treatment of haematological cancers, but is increasingly used in the treatment of patients severely affected by autoimmune diseases (ADs). In fact, ADs have become the fastest growing indication for aHSCT. A wide range of diseases have been treated, but the field has focused on three areas: multiple sclerosis, diffuse cutaneous systemic sclerosis and Crohn's disease, where there are populations of patients for whom disease control remains unsatisfactory despite the advent of biological and targeted small molecule therapies. Scientific studies of immune reconstitution have provided support for a 'rebooting' of the immune system through a re-diversification of naive and regulatory immune effector cells. In addition, there may be health economic benefits from a single one-off procedure. Even so, the treatment with aHSCT is intensive with a range of toxicities and risks which, despite being routine to transplant haematologists, are less familiar to disease specialists. Close collaboration between transplant haematologists and relevant disease specialists in patient selection, clinical management and follow-up is mandatory. Ideally, patients should be treated on a clinical trial if available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.